中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2012年
30期
2144-2147
,共4页
王晓芳%陆慰萱%郭军%李国%张运剑
王曉芳%陸慰萱%郭軍%李國%張運劍
왕효방%륙위훤%곽군%리국%장운검
高血压,肺性%野百合碱%大鼠%罗格列酮
高血壓,肺性%野百閤堿%大鼠%囉格列酮
고혈압,폐성%야백합감%대서%라격렬동
Hypertension,pulmonary%Monocrotaline%Rats%Rosiglitazone
目的 探讨罗格列酮早期干预对野百合碱诱导动脉型肺动脉高压大鼠肺血管病变的作用及机制.方法 32只SD大鼠随机分为对照组、模型组及罗格列酮高、低剂量干预组,每组8只.对照组大鼠皮下注射生理盐水后常规饲养,模型组及罗格列酮高、低剂量干预组大鼠皮下注射野百合碱60 mg/kg,注射当日起分别以生理盐水(1.5 ml/d)、罗格列酮(5 mg/kg及2.5 mg/kg)每日1次灌胃.21 d后测定各组大鼠肺动脉平均压(mPAP),取肺组织观察肺小动脉周围炎症评分,测定肺小动脉管壁中膜厚度占管壁外径百分比(WT%),酶联免疫吸附(ELISA)法测定肺组织匀浆白细胞分素6(IL-6)、肿瘤坏死因子α(TNF-α)和单核细胞趋化蛋白1(MCP-1)水平.结果 罗格列酮高、低剂量干预组mPAP[ (27±4)、(28 ±4) mm Hg(1 mm Hg =0.133 kPa)]和WT%(13.1%±3.9%、16.7%±1.7%)较模型组[(37±5) mm Hg和45.5%±5.5%]明显低(P<0.01),但仍高于对照组[(17±3)mm Hg和8.9%±2.3%](P<0.05和P<0.01);罗格列酮高、低剂量干预组肺小动脉周围炎症评分、肺组织匀浆IL-6、TNF-α及MCP-1水平均明显低于模型组(均P<0.01);罗格列酮高剂量干预组各项指标较低剂量干预组有降低趋势(P>0.05).结论 罗格列酮早期应用可延缓野百合碱诱导的大鼠动脉型肺动脉高压形成及肺血管重构,该作用可能与其抗炎作用有关,其对肺血管的保护作用与剂量有关.
目的 探討囉格列酮早期榦預對野百閤堿誘導動脈型肺動脈高壓大鼠肺血管病變的作用及機製.方法 32隻SD大鼠隨機分為對照組、模型組及囉格列酮高、低劑量榦預組,每組8隻.對照組大鼠皮下註射生理鹽水後常規飼養,模型組及囉格列酮高、低劑量榦預組大鼠皮下註射野百閤堿60 mg/kg,註射噹日起分彆以生理鹽水(1.5 ml/d)、囉格列酮(5 mg/kg及2.5 mg/kg)每日1次灌胃.21 d後測定各組大鼠肺動脈平均壓(mPAP),取肺組織觀察肺小動脈週圍炎癥評分,測定肺小動脈管壁中膜厚度佔管壁外徑百分比(WT%),酶聯免疫吸附(ELISA)法測定肺組織勻漿白細胞分素6(IL-6)、腫瘤壞死因子α(TNF-α)和單覈細胞趨化蛋白1(MCP-1)水平.結果 囉格列酮高、低劑量榦預組mPAP[ (27±4)、(28 ±4) mm Hg(1 mm Hg =0.133 kPa)]和WT%(13.1%±3.9%、16.7%±1.7%)較模型組[(37±5) mm Hg和45.5%±5.5%]明顯低(P<0.01),但仍高于對照組[(17±3)mm Hg和8.9%±2.3%](P<0.05和P<0.01);囉格列酮高、低劑量榦預組肺小動脈週圍炎癥評分、肺組織勻漿IL-6、TNF-α及MCP-1水平均明顯低于模型組(均P<0.01);囉格列酮高劑量榦預組各項指標較低劑量榦預組有降低趨勢(P>0.05).結論 囉格列酮早期應用可延緩野百閤堿誘導的大鼠動脈型肺動脈高壓形成及肺血管重構,該作用可能與其抗炎作用有關,其對肺血管的保護作用與劑量有關.
목적 탐토라격렬동조기간예대야백합감유도동맥형폐동맥고압대서폐혈관병변적작용급궤제.방법 32지SD대서수궤분위대조조、모형조급라격렬동고、저제량간예조,매조8지.대조조대서피하주사생리염수후상규사양,모형조급라격렬동고、저제량간예조대서피하주사야백합감60 mg/kg,주사당일기분별이생리염수(1.5 ml/d)、라격렬동(5 mg/kg급2.5 mg/kg)매일1차관위.21 d후측정각조대서폐동맥평균압(mPAP),취폐조직관찰폐소동맥주위염증평분,측정폐소동맥관벽중막후도점관벽외경백분비(WT%),매련면역흡부(ELISA)법측정폐조직균장백세포분소6(IL-6)、종류배사인자α(TNF-α)화단핵세포추화단백1(MCP-1)수평.결과 라격렬동고、저제량간예조mPAP[ (27±4)、(28 ±4) mm Hg(1 mm Hg =0.133 kPa)]화WT%(13.1%±3.9%、16.7%±1.7%)교모형조[(37±5) mm Hg화45.5%±5.5%]명현저(P<0.01),단잉고우대조조[(17±3)mm Hg화8.9%±2.3%](P<0.05화P<0.01);라격렬동고、저제량간예조폐소동맥주위염증평분、폐조직균장IL-6、TNF-α급MCP-1수평균명현저우모형조(균P<0.01);라격렬동고제량간예조각항지표교저제량간예조유강저추세(P>0.05).결론 라격렬동조기응용가연완야백합감유도적대서동맥형폐동맥고압형성급폐혈관중구,해작용가능여기항염작용유관,기대폐혈관적보호작용여제량유관.
Objective To investigate the protective effects of rosiglitazone intervention on monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) in rats and the possible mechanisms.Methods Thirty-two Sprague-Dawley rats were randomly divided into 4 groups:control group with a subcutaneous injection of normal saline.PAH group,high-dose and low-dose rosiglitazone intervention groups all with a subcutaneous injection of MCT and then gastric infusion of normal saline ( 1.5 ml/d),rosiglitazone (5,2.5 mg· kg-1 · d-1).At Day 21,the mean pulmonary arterial pressure (mPAP) was detected by right heart catheter. Then rats were sacrificed and their lungs extracted. Perivascular inflammation was scored with the subjective scale of 0 to 4.The tunica media thickness percentage of small pulmonary arteries ( WT% ) of rats was calculated.Interleukin 6 ( IL-6),tumor necrosis factor alpha ( TNF-α) and monocyte chemotactic protein 1 (MCP-1) of lung tissue were detected by enzyme-linked immunosorbent assay (ELISA).Results Compared with the PAH group ( ( 37 ± 5 ) mm Hg ( 1 mm Hg =0.133 kPa),45.5% ±5.5%),the mPAP and WT% of the high-dose ((27 ±4) mm Hg,13.1% ±3.9% ) and low-dose ( ( 28 ± 4 ) mm Hg, 16.7% ± 1.7% ) rosiglitazone intervention group were significantly lower ( P < 0.01 ),but were still higher than those of the control group ( ( 17 ± 3 ) mm Hg,8.9% ± 2.3% ) ( P < 0.05 or P < 0.01 ).The perivascular inflammation score and levels of IL-6,TNF-α,MCP-1 of high-dose and low-dose rosiglitazone intervention groups were significantly lower than those of the PAH group (P <0.01 ).Compared with the low-dose rosiglitazone intervention group,all the above indices of the high-dose rosiglitazone intervention group appeared much lower (P > 0.05 ).Conclusion The protective effects of rosiglitazone against MCT-induced PH are correlated with drug dose and may be due to the inhibition of inflammation.